Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study

Covid19 Clinical Trial

Official title:

Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04888793
• Other study ID #: 210405014
• Status: Completed
• Start date: May 12, 2021
• Est. completion date: November 1, 2021

Study information

• Verified date: May 2021
• Source: Pontificia Universidad Catolica de Chile
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Despite COVID-19 pandemic having started more than one year ago, there are still limited treatment options for these patients, and over 145 million cases and 3 millions deaths have ensued worldwide. Fortunately, SARSCoV2 vaccines have been developed at an unprecedented pace. While the vaccination programs are still ongoing, early reports on efficacy are mainly centered on healthy population. In Chile most people have received the inactivated Coronavac vaccine. Data on the immune response after vaccination in immunocompromised patients is lacking. Therefore, this study aims to evaluate the immune response after Coronavac vaccine in 5 cohorts of immunocompromised patients and healthy controls. We will include patients with cancer, HIV, solid organ transplant and patients receiving immunomodulatory agents for rheumatic diseases.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 260
• Est. completion date: November 1, 2021
• Est. primary completion date: September 1, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

General Inclusion Criteria:

• Eastern Cooperative Oncology Group < 3
• Vaccination with 2 doses of Coronavac vaccine

General Exclusion Criteria:

• Previous SARS-CoV-2 infection
• Vaccination with Coronavac more than 12 weeks before informed consent
• Intravenous immunoglobulin therapy 60 days before informed consent
• Any condition, that could interfere with the participant's participation during the study in the opinion of the treating investigator. Cancer Cohort

Inclusion Criteria:

• Diagnosis of cancer in the previous 5 years (consistent biopsy is required).
• Life expectancy more than 12 weeks

Exclusion Criteria:

• Bone marrow transplant, solid organ recipient, HIV, immunosuppressant treatment for other condition. Bone Marrow Transplant Cohort

Inclusion Criteria:

• Bone marrow transplant between January 2019 and December 2020

Exclusion Criteria:

• Other cancer diagnosis during the last 5 years, solid organ recipient, HIV, immunosuppressant treatment for other condition. Solid Organ Recipient Cohort:

Inclusion Criteria:

• Liver, kidney or heart transplant between January 2019 and December 2020
• Active immunosuppressant treatment

Exclusion Criteria:

• Cancer diagnosis during the last 5 years, bone marrow transplant, immunosuppressant treatment for other condition, HIV HIV Cohort:

Inclusion Criteria:

• CD4 <= 500 cels/mm3 documented one year before study enrollment
• Active antiretroviral therapy
• Viral load < 200 copies/ml

Exclusion Criteria:

• Cancer diagnosis during the last 5 years, bone marrow transplant or solid organ recipient, immunosuppressant treatment. Rheumatic Disease Cohort

Inclusion Criteria:

• Diagnosis of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, relapsing polychondritis, Behcet disease or juvenile idiopathic arthritis
• Chronic immunomodulatory treatment with anti-TNF, anti-IL6 or anti-IL17 agents

Exclusion Criteria:

• Treatment with more than one biological agent.
• Cancer diagnosis during the last 5 years, bone marrow transplant or solid organ recipient, HIV diagnosis.

Related Conditions & MeSH terms

• COVID-19
• COVID-19 Vaccines
• Covid19

Intervention

Diagnostic Test:
• Serologic immune response evaluation
Detection of total and neutralizing antibodies against SARS-CoV-2

Locations

Country	Name	City	State
Chile	Red de Salud UC Christus	Santiago

Sponsors (1)

Lead Sponsor	Collaborator
Pontificia Universidad Catolica de Chile

Country where clinical trial is conducted

Chile, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of positive neutralizing antibodies 8 to12 weeks after Coronavac vaccine		8 to12 weeks after Coronavac vaccine
Secondary	Neutralizing geometric mean titers 8 to12 weeks after Coronavac vaccine		8 to12 weeks after Coronavac vaccine